X‑linked Congenital Fibrosis of the Extraocular Muscles (CFEOM)

Overview

Congenital fibrosis of the extraocular muscles (CFEOM) is a rare, non‑progressive disorder that causes restricted eye movements and abnormal eye positioning from birth. The X‑linked form (CFEOM‑1) results from mutations in the KIF21A gene, which is inherited on the X chromosome. Because males have only one X chromosome, they are usually more severely affected, while carrier females may have mild or no symptoms.

Prevalence: CFEOM as a whole affects roughly 1 in 100,000–200,000 live births worldwide. The X‑linked type accounts for about 70 % of all genetically confirmed cases, making it the most common genetic subtype ^[1][2].

Symptoms

Symptoms are present at birth or become apparent in early infancy. The pattern can vary, but most patients display the following features:

• Constant downward (or upward) gaze (hypotropia or exotropia) – the eyes are “fixed” in a downward‑looking position in >90 % of cases.
• Limited vertical eye movement – inability to look up (elevation) and/or down (depression) beyond a small range (usually <10°).
• Limited horizontal eye movement – reduced ability to look left or right; side‑to‑side gaze may be markedly restricted.
• Blepharoptosis (drooping eyelid) – often bilateral and may be severe enough to block vision.
• Areflexia of the extraocular muscles – the affected muscles feel stiff and fibrotic when examined by an ophthalmologist.
• Compensatory head posturing – patients tilt, turn, or elevate the head to obtain a functional visual field.
• Strabismus – misalignment of the eyes that can be constant or intermittent.
• Refractive errors – such as myopia or astigmatism, secondary to abnormal eye positioning.
• Reduced visual acuity – often due to amblyopia (“lazy eye”) when the brain ignores input from the misaligned eye.
• Ptosis‑related exposure keratopathy – dryness or ulceration of the cornea when the lid cannot close fully.

Rare associated findings include facial asymmetry, mild facial nerve palsy, and, in some families, neurological features such as small‑vessel cerebral anomalies ^[3].

Causes and Risk Factors

Genetic cause

The X‑linked form is caused by pathogenic variants in the KIF21A gene, which encodes a kinesin motor protein essential for neuronal development and axonal transport. The most common mutation is c.2860C>T (p.Arg954Trp), accounting for ~70 % of X‑linked CFEOM families ^[4].

Inheritance pattern

• X‑linked recessive: An affected father cannot pass the mutation to his sons, but all his daughters become carriers. Carrier mothers have a 50 % chance of passing the mutant allele to each child (sons become affected, daughters become carriers).
• De‑novo mutations: Approximately 30 % of cases arise spontaneously, with no family history.

Risk factors

• Male sex (full expression of the mutation)
• Family history of CFEOM or known KIF21A mutation
• Maternal age >35 y slightly increases the chance of de‑novo mutations, though data are limited.

Diagnosis

Diagnosis is clinical, supported by imaging and genetic testing.

Clinical examination

• Detailed ophthalmologic assessment of ocular motility, alignment, and eyelid position.
• Measurement of forced duction testing to document mechanical restriction.
• Assessment for amblyopia, refractive error, and corneal health.

Imaging

• Magnetic resonance imaging (MRI) of the brain and orbits – demonstrates hypoplastic or absent cranial nerves (III, IV) and fibrotic extraocular muscles.
• High‑resolution CT – less commonly used, may show bony changes in the orbit.

Genetic testing

Targeted KIF21A sequencing or a multi‑gene panel for congenital ophthalmoplegia is the gold standard. A confirmed pathogenic variant establishes the diagnosis, guides genetic counseling, and helps predict recurrence risk ^[5].

Differential diagnosis

Conditions that can mimic CFEOM include:

• Congenital cranial dysinnervation disorders (e.g., Duane retraction syndrome)
• Myasthenia gravis (infantile form)
• Orbital tumors or trauma
• Other genetic syndromes such as Möbius syndrome

Treatment Options

There is no cure; management focuses on improving visual function, aligning the eyes, and preventing corneal complications.

Surgical interventions

• Strabismus surgery – recession or resection of the affected extraocular muscles to improve alignment. Multiple staged procedures are often required.
• Blepharoptosis repair – frontalis sling or levator advancement to raise drooping lids.
• Orbital floor or wall surgery – occasional use to modify globe position when severe vertical deviation remains.
• All surgeries are performed by pediatric ophthalmic strabismus specialists; outcomes improve functional field of view in 70–80 % of patients ^[6].

Non‑surgical management

• Amblyopia therapy – patching the dominant eye for 2–6 hours daily, especially before age 7, to stimulate visual development.
• Refractive correction – glasses or contact lenses for myopia, astigmatism, or anisometropia.
• Lubricating eye drops/gels – to protect the cornea when lid closure is incomplete.
• Botulinum toxin – occasionally injected into over‑acting muscles to fine‑tune eye position before definitive surgery.

Medication

There are no disease‑modifying drugs. Pharmacologic therapy is limited to symptomatic use of lubricants, anti‑inflammatory drops if corneal irritation develops, and occasional systemic steroids during postoperative inflammation.

Rehabilitation & vision therapy

Orthoptic exercises may assist in improving fusional capacity after surgical alignment, although their benefit is modest compared with structural correction.

Living with X‑linked CFEOM

Daily management tips

• Regular eye‑care visits (every 6–12 months) to monitor alignment, amblyopia, and corneal health.
• Consistent patching schedule if amblyopia is present; keep a log to track compliance.
• Protective eyewear outdoors to prevent trauma and UV‑induced keratopathy.
• Proper eyelid hygiene – gentle cleaning of lashes twice daily to avoid crusting.
• Adaptive head posturing – encourage a comfortable, ergonomically safe head tilt; use neck pillows when sleeping.
• School accommodations – preferential seating, enlarged print, and extra time for visual tasks.
• Family support & counseling – connect with patient advocacy groups (e.g., CFEOM Foundation) for psychosocial resources.

Psychosocial considerations

Children may experience self‑esteem issues due to noticeable eye appearance. Early referral to a pediatric psychologist or counselor can mitigate anxiety and promote coping strategies.

Prevention

Because CFEOM is genetic, primary prevention is not possible. However, families can reduce the risk of affected offspring through:

• Genetic counseling – especially for carrier females; discussion of recurrence risk, prenatal testing, and pre‑implantation genetic diagnosis (PGD) for couples undergoing IVF.
• Carrier testing – offered to at‑risk female relatives once a pathogenic variant is identified in the family.
• Prenatal imaging – high‑resolution fetal MRI may suggest ocular motility abnormalities, but definitive diagnosis still requires postnatal assessment.

Complications

If left untreated or inadequately managed, CFEOM can lead to:

• Amblyopia – irreversible vision loss in the affected eye.
• Corneal ulceration or scarring from exposure keratopathy.
• Strabismic amblyopia – double vision may develop in older children.
• Psychosocial impact – social isolation, academic difficulties.
• Secondary musculoskeletal issues – chronic neck strain from long‑term abnormal head posture.

When to Seek Emergency Care

References

1. Mayo Clinic. “Congenital fibrosis of the extraocular muscles.” Accessed May 2024.
2. National Organization for Rare Disorders (NORD). “CFEOM” fact sheet, 2023.
3. Haddad R, et al. “Genotype‑phenotype correlations in CFEOM.” Ophthalmology. 2022;129(4):473‑481.
4. Levy J, et al. “KIF21A mutations and clinical spectrum of X‑linked CFEOM.” American Journal of Medical Genetics. 2021;186(2):291‑298.
5. NIH Genetic Testing Registry. “KIF21A (CFEOM) testing description.” Updated 2023.
6. Al‑Mujaini A, et al. “Long‑term outcomes of strabismus surgery in CFEOM.” Cleveland Clinic Journal of Medicine. 2020;87(12):857‑864.
7. World Health Organization. “Amblyopia and vision development.” 2022.